CD4 and leukemia: Therefore, we conjecture that lower level expression of costimulatory molecules on LEXs than that on DEX may be the main defect for LEXs-targeted CD4+ T cells to induce high-level anti-leukemia immunity, since costimulatory molecule gene-modified LEXs could significantly enhance their anti-leukemia immunity in our recent study (35).